NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
08/27/2024
Back to search
Official data from USPTO
CONQUEST SCLERODERMA RESEARCH FOUNDATION CLINICAL TRIAL PLATFORM
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
28
Latest update
08/27/2024
Classification
Registered
Trademark type
Combined
Nice classes
42
Filing date
02/14/2023
Registration date
08/27/2024
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
08/27/2024
Last transaction
08/27/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
First use anywhere
02/01/2023
First use in commerce
02/01/2023
Drawing code
3
Owner type
54
Owner location
San Francisco, CA
Examiner
BROWN, TINA
Law office
M90
Current location
FILE REPOSITORY (FRANCONIA)
Mark description
The mark consists of the stylized word "CONQUEST" in blue, with the image of three caret-shaped symbols in blue appearing above the letters "UEST" in "CONQUEST", with each caret-shaped symbol consisting of two rows of dots with the size of the dots increasing in each caret-shaped symbol going from left to right, and the stylized words "SCLERODERMA RESEARCH FOUNDATION" appearing in light blue immediately beneath the word "CONQUEST", and the stylized words "CLINICAL TRIAL PLATFORM" appearing in light blue immediately beneath the words "SCLERODERMA RESEARCH FOUNDATION".
Holders and representatives
Holders
S. F. (pessoa física)
Representatives
J. Scott Gerien DICKENSON, PEATMAN & FOGARTY
Technical classification
Nice Classes
Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 42
Medical and scientific researchconducting clinical trials for others
Publications
History of USPTO decisions and trademark events.
28 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
08/27/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
06/11/2024
PUBO
PUBLISHED FOR OPPOSITION
06/11/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
05/22/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
05/04/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
05/03/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/03/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
05/03/2024
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
02/11/2024
GNRT
NON-FINAL ACTION E-MAILED
02/11/2024
CNRT
NON-FINAL ACTION WRITTEN
02/11/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/05/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/04/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/04/2024
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
01/04/2024
GNRT
NON-FINAL ACTION E-MAILED
01/04/2024
CNRT
NON-FINAL ACTION WRITTEN
01/04/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/09/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/08/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/08/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
11/13/2023
GNRT
NON-FINAL ACTION E-MAILED
11/13/2023
CNRT
NON-FINAL ACTION WRITTEN
11/13/2023
DOCK
ASSIGNED TO EXAMINER
11/13/2023
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
03/07/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
03/05/2023
NWAP
NEW APPLICATION ENTERED
02/17/2023
Continuous trademark protection
Get notified about every new filing that threatens CONQUEST SCLERODERMA RESEARCH FOUNDATION CLINICAL TRIAL PLATFORM or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.